Glowise editorial guide

Mounjaro vs Zepbound: Why the Tirzepatide Brand Still Matters

Both products contain tirzepatide. Understand their different U.S. indications, age groups, treatment goals, and presentations before comparing prescriptions.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 19, 20267 min read
Download the Glowise App

Share this guide

Xfin
Two unbranded medicine cartons beside separate care-plan folders

Mounjaro and Zepbound are both once-weekly tirzepatide injections. The U.S. brand names identify prescriptions approved for different jobs. Mounjaro is approved for blood sugar control in type 2 diabetes and for reducing certain cardiovascular risks in specified adults with type 2 diabetes. Zepbound is approved for long-term weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.

That distinction matters when a pharmacy offers the other brand. Before deciding what to fill, find out what your prescriber is treating and what is blocking the original prescription. Then confirm the exact product and device you would receive.

What are Mounjaro and Zepbound approved to treat?

Treatment goalMounjaroZepbound
Improve blood sugar in type 2 diabetesAdults and children aged 10 and older, along with diet and exerciseNo labeled indication for glucose control
Reduce the risk of major cardiovascular eventsAdults with type 2 diabetes at high risk for major cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke)No labeled indication for this purpose
Lose excess weight and maintain weight loss long termNo labeled indication for weight managementAdults with obesity or adults with overweight and at least one weight-related condition
Treat obstructive sleep apneaNo labeled indication for sleep apneaAdults with obesity and moderate-to-severe obstructive sleep apnea

Zepbound's two indications include a reduced-calorie diet and increased physical activity. The full prescribing information defines the approved uses and the dose recommendations for each product. Mounjaro U.S. prescribing information · Zepbound U.S. prescribing information

If your clinician wrote Mounjaro for type 2 diabetes and weight is also a concern, ask, “Which goal are we treating with this prescription, and how will we track it?” Weight change can be part of that conversation. If you have obesity and moderate-to-severe obstructive sleep apnea, ask your sleep clinician how a Zepbound prescription would fit into your existing care, including what to do with any prescribed PAP therapy. The two situations can involve the same ingredient and call for different follow-up.

Both brands come in several of the same strengths. The dose plan still depends on who is taking the medicine and why. For children aged 10 and older with type 2 diabetes, Mounjaro's labeled maximum is 10 mg weekly. For adults taking Zepbound, the labeled weekly maintenance doses are 10 or 15 mg for sleep apnea and 5, 10 or 15 mg for weight management. If a pharmacist or plan offers another product in your current strength, ask your prescriber which dose fits the condition being treated before you switch. Mounjaro prescribing information, section 2.1 · Zepbound prescribing information, section 2.2

Is either brand better for weight loss?

Zepbound has the U.S. weight-management indication. To compare the weight-loss figures you see for the two brands, first check who took the medicine and what the study measured. In Zepbound's prescribing information, two 72-week weight-management studies tested tirzepatide against placebo. At the same studied dose of 15 mg, average weight loss was 20.9% versus 3.1% with placebo among adults with obesity or overweight with a weight-related condition. That trial excluded people with type 2 diabetes. In the trial that enrolled adults with type 2 diabetes and a BMI of 27 or higher, it was 14.7% versus 3.2% with placebo. The populations differed even though both trials studied Zepbound. Comparing those averages with results from a separate Mounjaro diabetes trial cannot tell you whether changing the name on the prescription would change your results. Zepbound prescribing information, section 14.1

If the actual decision is whether to discuss a different active ingredient, start with the U.S. GLP-1 medications list for the products and their labeled uses.

What should you ask if the pharmacy cannot fill your prescription?

Say your Zepbound refill is due on Friday. The pharmacy says it cannot fill it and asks whether you can use Mounjaro. A stock problem and an insurance rejection can sound the same at the counter. The answer comes from different people.

  1. Ask the pharmacist what stopped the fill. “Is my exact Zepbound product out of stock, or did my plan reject the claim? What did the rejection say?” If stock is the issue, ask whether they can get the prescribed product in time or help locate it at another pharmacy.
  2. Ask the plan what it requires. If the issue is coverage, ask, “For this brand, device, and the condition my clinician is treating, is it covered? Does the plan need prior authorization, or does my prescription have to go to a different pharmacy?” Ask for the expected out-of-pocket cost once those requirements are met. If the plan suggests Mounjaro, give your prescriber the exact reason and suggested product.
  3. Ask the prescriber what to do about the upcoming dose. Give them the rejection or stock update, the medication and device you use, the date of your last actual dose, and when the next one is due. If your prescriber proposes a change, get the new prescription instructions in writing, including the dose, when to take it and when to follow up. Use one agreed plan and avoid using both brands together. The Zepbound label advises against using it with another tirzepatide product or a GLP-1 receptor agonist. Zepbound prescribing information, section 1

A pharmacy may also suggest a compounded product. That raises a separate set of questions about approval, sourcing and dose concentration. Zepbound vs. compounded tirzepatide

What if your refill comes with a different device?

Ask the pharmacist to show you how to use the supplied device before taking the next dose. Both U.S. labels list a single-dose pen, single-dose vial, multi-dose vial and four-dose KwikPen for one patient. Ask which one your pharmacy will actually dispense. A refill can keep the same brand name but come with a different device and instructions.

For example, a four-dose carton labeled 20 mg total can supply four 5 mg doses. The milligrams printed for the entire pen or vial and the milligrams prescribed for one injection answer different questions. If you receive a new pen or vial, show the pharmacist the carton and ask, “What is the dose per injection on this prescription, and can you show me how to measure or deliver it with this exact device?” Follow the instructions supplied for that device. A vial measurement from a previous refill can be wrong for the new one. Mounjaro prescribing information, sections 2 and 3 · Zepbound prescribing information, sections 2 and 3

Bring side effects or medication concerns to the same conversation. For example, if you're seeking a different brand because of nausea, tell your prescriber when it started and whether it followed a dose increase. Nausea is reported with both products. If you take insulin or a sulfonylurea, ask what glucose monitoring your clinician wants, since using tirzepatide with either can increase the risk of low blood sugar. Mounjaro prescribing information, sections 5 and 6 · Zepbound prescribing information, sections 5 and 6

Both labels rule out use if you or a family member has had medullary thyroid cancer, if you have multiple endocrine neoplasia type 2, or if you've had a serious allergic reaction to tirzepatide or an inactive ingredient in the product. If you're using an oral hormonal contraceptive, both labels advise using a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase. Ask your prescriber how that applies to your plan and see the full warnings in the label for the product you're considering. Mounjaro prescribing information, sections 4, 5 and 8.3 · Zepbound prescribing information, sections 4, 5 and 8.3

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.